Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.contributor.authorArpaci, Erkan
dc.contributor.authorYetisyigit, Tarkan
dc.contributor.authorSeker, Metin
dc.contributor.authorUncu, Dogan
dc.contributor.authorUyeturk, Ummugul
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorDemirci, Umut
dc.date.accessioned2024-04-24T16:02:41Z
dc.date.available2024-04-24T16:02:41Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with Ewing sarcoma family of tumors (ESFT). Data of patients with ESFTs followed up at different cancer centers in Turkey between 2001 and 2010 were retrospectively analyzed. The median age of 114 patients was 26 years (range 14-66). The median follow-up was 20 months (range 1-118 months). Tumor size was between 1.5 and 14 cm (median 8 cm). Eighty-six percent of patients had localized disease at presentation, and 14 % had metastatic disease. Local therapy was surgery alone in 31 % of patients, surgery combined with radiotherapy in 41 % and radiotherapy alone in 18 %. Approximately 70 % of patients were treated with vincristine, doxorubicin, cyclophosphamide and actinomycin-D, alternating with ifosfamide and etoposide every 3 weeks. In patients with localized disease at presentation, the 5-year disease-free survival and overall survival were 60 and 65 %, respectively. At univariate analysis, patients with tumor size >= 8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size <= 8 cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ESFTs are aggressive tumors with a high incidence of local recurrence and distant metastasis. Multimodality treatment consisting of adequate surgical resection, aggressive chemotherapy (VAC alternating with IE) and radiotherapy is recommended for patients with ESFTs.en_US
dc.identifier.doi10.1007/s12032-013-0469-z
dc.identifier.issn1357-0560
dc.identifier.issue1en_US
dc.identifier.pmid23345116
dc.identifier.scopus2-s2.0-84880576746
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s12032-013-0469-z
dc.identifier.urihttps://hdl.handle.net/11468/14877
dc.identifier.volume30en_US
dc.identifier.wosWOS:000316800800145
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEwing's Sarcomaen_US
dc.subjectSurgeryen_US
dc.subjectChemotherapyen_US
dc.titlePrognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncologyen_US
dc.titlePrognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu